We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Imagine HIV patients needed to take their antiretroviral therapies not every day, not even every month, but every two months. A GlaxoSmithKline two-drug injectable regimen that’s already under review by the FDA for monthly use could soon turn it into real